셀리악병 치료제 시장 : 세계 예측(2026-2032년)

The Celiac Disease Drugs Market is projected to grow by USD 2.57 billion at a CAGR of 10.33% by 2032.

Celiac disease drugs are emerging as a critical therapeutic focus as the limitations of a lifelong gluten-free diet become increasingly evident. Celiac disease is an autoimmune enteropathy triggered by gluten in genetically predisposed individuals, leading to intestinal inflammation, villous atrophy, malabsorption, and systemic complications when inadequately controlled. While strict dietary avoidance remains the standard of care, real-world exposure to hidden gluten, variable adherence, persistent symptoms, and refractory celiac disease have created a clear clinical need for pharmacological interventions. Drug development is concentrated on mechanisms that reduce gluten immunogenicity, block immune activation, protect the intestinal barrier, modulate inflammatory pathways, or induce immune tolerance. Key therapeutic approaches include oral gluten-degrading enzymes, transglutaminase 2 inhibitors, tight junction regulators, cytokine-targeting agents, and antigen-specific immunotherapies. The clinical landscape is shaped by improved serological testing, greater physician awareness, and increased recognition of non-dietary disease burden, including anemia, osteoporosis, infertility, neurological symptoms, and reduced quality of life. Regulatory and clinical momentum is also supported by validated endpoints such as histology, symptom scores, gluten challenge models, and biomarker-based patient stratification. As the celiac disease drugs pipeline advances, stakeholders are prioritizing safety, long-term tolerability, pediatric applicability, and compatibility with dietary management. The sector is transitioning from symptom control toward disease-modifying and exposure-protection strategies designed to address unmet needs in patients with ongoing gluten sensitivity, accidental exposure, or inadequate response to dietary therapy.

Transformative Shifts in the Celiac Disease Drug Landscape

The celiac disease drugs landscape is being reshaped by the shift from diet-only management toward targeted pharmaceutical intervention. Historically, the gluten-free diet served as the sole practical treatment, but clinical evidence shows that some patients continue to experience intestinal injury or symptoms despite reported adherence, often due to cross-contamination, hidden gluten, or incomplete gluten exclusion. This has accelerated interest in adjunct therapies that can reduce mucosal damage and improve daily disease control without replacing dietary discipline. Another transformative shift is the movement from broad anti-inflammatory concepts to mechanism-specific drug design. Developers are increasingly focusing on transglutaminase 2 inhibition to reduce deamidation of gluten peptides, enzymatic detoxification of gluten before immune activation, and intestinal permeability modulation to reduce antigen passage. Immunology-led innovation is also gaining importance, with therapies designed to retrain gluten-specific immune responses and reduce T-cell activation. Clinical development is becoming more patient-centered, emphasizing symptom burden, accidental gluten exposure, histological healing, serologic response, and measurable improvements in quality of life. Diagnostic advances are also influencing the treatment pathway, as serological screening, HLA-DQ2 and HLA-DQ8 association testing, endoscopic confirmation, and biomarker research enable better identification of eligible patients. In parallel, regulators and clinicians are demanding robust evidence of safety because many patients may require chronic or repeated therapy. These shifts are positioning celiac disease drugs as adjunctive, preventive, and potentially disease-modifying solutions within a broader autoimmune gastrointestinal care model.

Cumulative Impact of AI on Celiac Disease Drug Development

Artificial intelligence is influencing celiac disease drug discovery, clinical trial design, patient stratification, and real-world disease management. In early-stage research, AI-enabled protein modeling, immunopeptidomics analysis, and computational screening can help identify gluten epitopes, enzyme candidates, small-molecule inhibitors, and immune-modulating targets relevant to celiac pathophysiology. Machine learning models are increasingly useful for interpreting complex datasets from genomics, transcriptomics, microbiome studies, serology, histopathology, and patient-reported outcomes, enabling more precise understanding of disease heterogeneity. In clinical development, AI can improve trial feasibility by identifying patients with persistent symptoms, confirmed diagnosis, genetic susceptibility, or evidence of active mucosal injury, thereby supporting enrichment strategies and reducing variability. Digital tools also support remote symptom tracking, dietary exposure assessment, adherence monitoring, and detection of patterns associated with accidental gluten ingestion. AI-assisted pathology has potential to standardize villous height, crypt depth, and intraepithelial lymphocyte assessment, improving consistency in histological endpoints. Natural language processing can extract insights from electronic health records to identify underdiagnosed patients, delayed diagnosis patterns, comorbid autoimmune conditions, and care gaps. However, adoption depends on clinically validated algorithms, transparent data governance, bias mitigation, and compliance with privacy regulations. The cumulative impact of artificial intelligence is therefore not limited to faster discovery; it is expanding the evidence infrastructure needed for personalized celiac disease therapeutics, more efficient clinical trials, and better long-term monitoring of treatment response.

Key Regional Insights Across Celiac Disease Drug Adoption

In North America, celiac disease drug development benefits from advanced gastroenterology care pathways, high awareness of autoimmune gastrointestinal disorders, broad availability of tissue transglutaminase IgA testing, active clinical trial infrastructure, and strong patient advocacy supporting adjunct treatment demand. The United States and Canada show substantial readiness for therapies that address accidental gluten exposure and persistent symptoms, particularly where diagnosis is confirmed through standardized serology, duodenal biopsy when indicated, and specialist care. Europe remains highly influential due to established celiac disease guidelines, widespread use of gluten-free dietary standards, strong academic research in immunology and gastroenterology, and structured regulatory expectations for chronic therapies. Countries across Western and Southern Europe have mature diagnostic networks, while variation in reimbursement, gluten-free food support, and nutrition services affects patient access patterns. Asia-Pacific is gaining relevance as awareness and diagnosis improve across China, India, Japan, South Korea, Australia, and ASEAN economies. The region presents diverse clinical dynamics, including historically lower diagnosis rates in parts of Asia, changing wheat consumption patterns, expanding specialty care, and growing use of laboratory diagnostics. Latin America shows increasing recognition of celiac disease, particularly in Brazil and Mexico, supported by expanding gastroenterology services and public attention to gluten-related disorders, though access to specialist diagnosis and confirmatory testing varies by healthcare system. The Middle East is an important emerging region as autoimmune disease awareness rises and GCC healthcare systems invest in specialty diagnostics, tertiary care, and advanced therapeutics. Africa remains comparatively underdiagnosed, but increased availability of serology in urban centers, healthcare expansion, and growing recognition of autoimmune gastrointestinal disease are improving identification of patients who may benefit from future pharmacological options.

Key Group Insights Shaping Celiac Disease Drug Strategies

Across ASEAN, celiac disease drug relevance is tied to improving diagnostic capability, expanding private healthcare networks, and growing recognition that gluten-related autoimmune disease may be underdetected in populations with evolving dietary patterns. Adoption of future therapies will depend on physician education, laboratory access, dietitian availability, and integration with gluten-free dietary counseling. In the GCC, high investment in tertiary care, specialty hospitals, and advanced diagnostics supports early receptivity to innovative gastrointestinal and autoimmune therapies, particularly where chronic disease management programs are well developed. The European Union provides one of the most structured environments for celiac disease therapeutics due to harmonized regulatory pathways, established clinical guidance, strong pharmacovigilance requirements, and widespread public health attention to gluten-free labeling and patient protection. BRICS countries represent heterogeneous but strategically important demand environments: Brazil, Russia, India, China, and South Africa differ in diagnosis rates, reimbursement structures, wheat consumption, and specialist access, yet collectively reflect growing autoimmune disease recognition and expanding pharmaceutical research capabilities. The G7 economies have advanced clinical trial ecosystems, sophisticated regulatory frameworks, and high standards for evidence generation, making them central to late-stage validation and early clinical uptake of celiac disease drugs. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where resilient medical supply chains, regulatory quality, and cross-border research collaboration can support stable access to chronic therapies. Across these groups, the strongest opportunities are linked to evidence-backed safety, clear clinical endpoints, compatibility with gluten-free diets, and cost-effective integration into long-term celiac disease care.

Key Country Insights for Celiac Disease Drug Development

The United States is a leading environment for celiac disease drug research due to strong clinical trial activity, gastroenterology specialization, patient advocacy, and high demand for therapies that protect against accidental gluten exposure. Canada shows similar clinical priorities, with emphasis on evidence-based care, diagnostic confirmation, and safe adjunct treatment options for persistent symptoms. Mexico and Brazil are advancing in disease recognition as gastroenterology access improves and public understanding of gluten-related disorders increases, although diagnostic consistency, specialist access, and reimbursement remain important considerations. In the United Kingdom, structured clinical guidance and high awareness of gluten-free management support readiness for therapies that address persistent symptoms or mucosal damage. Germany and France offer strong research and specialty care infrastructure, while Italy and Spain have well-established celiac disease awareness, dietary management systems, and clinical expertise that can support adoption of validated treatments. Russia presents opportunities linked to expanding specialist care and autoimmune disease diagnostics, though access dynamics vary by region. China and India are increasingly important as diagnosis expands with changing dietary patterns, broader serological testing, and improved specialist awareness, making patient identification a central priority. Japan and South Korea combine advanced healthcare systems, high diagnostic quality, and strong clinical research capacity, although disease recognition, testing practices, and physician awareness continue to shape treatment pathways. Australia has a particularly active celiac disease community, strong diagnostic standards, and high awareness of gluten-free dietary challenges, making it receptive to adjunct therapies with clear safety and quality-of-life benefits. Across all countries, clinical uptake will depend on confirmed diagnosis, durable safety data, measurable symptom and histology benefits, and positioning as a complement rather than a substitute for gluten avoidance.

Actionable Recommendations for Celiac Disease Drug Leaders

Industry leaders should prioritize therapies that address clearly defined unmet needs, including protection from accidental gluten exposure, persistent symptoms despite dietary adherence, incomplete mucosal healing, and refractory celiac disease under specialist supervision. Clinical programs should incorporate validated diagnostic criteria, gluten challenge protocols where appropriate, histological endpoints, patient-reported outcomes, serological markers, and safety monitoring suitable for long-term or repeat use. Developers should design products as adjuncts to gluten-free diets rather than replacements, as this aligns with current clinical practice and patient expectations. Investment in patient stratification is essential, particularly around HLA status, disease activity, symptom phenotype, mucosal injury, comorbid autoimmune disease, and immune biomarkers. Stakeholders should strengthen collaboration with gastroenterologists, dietitians, immunologists, pathologists, and patient organizations to ensure real-world relevance and adherence-friendly treatment design. Regulatory strategies should emphasize chronic safety, pediatric development planning, drug-food interaction assessment, and evidence of clinically meaningful improvement beyond laboratory measures. Commercial readiness should include education for primary care and specialists to reduce diagnosis delays and improve referral pathways. Digital health tools can support symptom diaries, dietary exposure tracking, remote monitoring, and real-world evidence generation. For global access, industry leaders should tailor strategies to regional diagnostic maturity, reimbursement frameworks, gluten-free food infrastructure, and clinician familiarity. The most resilient strategies will combine strong mechanistic science, patient-centered endpoints, transparent safety evidence, and practical integration into lifelong celiac disease management.

Research Methodology for Celiac Disease Drug Insights

This executive summary is built using a structured secondary research methodology focused on verified clinical, regulatory, epidemiological, and scientific evidence related to celiac disease therapeutics. The research approach includes analysis of peer-reviewed medical literature, gastroenterology guidelines, autoimmune disease research, clinical trial registries, regulatory science publications, diagnostic standards, and recognized public health sources. Therapeutic mechanisms were assessed through evidence on celiac disease pathophysiology, including gluten peptide immunogenicity, HLA-DQ2 and HLA-DQ8 association, tissue transglutaminase activity, intestinal permeability, T-cell mediated immune response, mucosal inflammation, and villous atrophy. Regional, group, and country insights were developed by evaluating healthcare infrastructure, diagnostic availability, specialist access, clinical research maturity, gluten-free diet awareness, regulatory readiness, and public health policy without using market sizing, market share, or forecasting assumptions. The methodology emphasizes triangulation across multiple validated sources to reduce bias and improve reliability. Qualitative interpretation was applied to identify adoption enablers, development barriers, and therapeutic positioning themes. Artificial intelligence insights were derived from documented applications in drug discovery, trial optimization, digital pathology, real-world evidence, biomarker analysis, and patient monitoring. All findings are presented in an executive, SEO-optimized format for decision-makers while avoiding unsupported claims and excluding company-specific references. The result is a data-backed synthesis of the celiac disease drugs landscape, designed to support strategic planning, research prioritization, and evidence-based industry decision-making.

Conclusion on the Future of Celiac Disease Drugs

Celiac disease drugs represent a pivotal evolution in autoimmune gastrointestinal care, moving beyond exclusive reliance on gluten avoidance toward targeted, evidence-based therapeutic support. The most promising opportunities are concentrated in adjunct treatments that reduce the impact of accidental gluten exposure, improve persistent symptoms, support mucosal healing, or modulate the immune mechanisms driving disease activity. Regional readiness is strongest where diagnosis, specialist care, clinical trial infrastructure, and patient awareness are well developed, while emerging regions offer long-term potential as testing and physician recognition improve. Artificial intelligence is becoming an important accelerator across discovery, clinical development, biomarker analysis, pathology standardization, and real-world monitoring, but its value depends on validation, data quality, and responsible implementation. Industry leaders that align therapeutic innovation with patient needs, regulatory expectations, chronic safety requirements, and practical diet-based care will be best positioned to advance the field. Success will depend on demonstrating clinically meaningful benefits, maintaining compatibility with gluten-free management, and building confidence among patients, clinicians, regulators, and payers. As scientific understanding deepens, the celiac disease drugs landscape is expected to become more targeted, personalized, and integrated into comprehensive autoimmune care pathways.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Celiac Disease Drugs Market, by Drug Type

• 7.1. Introduction
• 7.2. Gluten-Degrading Enzyme Therapies
• 7.3. Tight Junction Regulators
• 7.4. Immunomodulators
• 7.5. Biologics

8. Celiac Disease Drugs Market, by Molecule Type

• 8.1. Introduction
• 8.2. Biological
• 8.3. Small Molecule
• 8.4. Peptide-Based Drugs

9. Celiac Disease Drugs Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Injectable
• 9.3. Oral

10. Celiac Disease Drugs Market, by End User

• 10.1. Introduction
• 10.2. Homecare Settings
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Celiac Disease Drugs Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Celiac Disease Drugs Market, by Age Group

• 12.1. Introduction
• 12.2. Adults
• 12.3. Pediatrics

13. Celiac Disease Drugs Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Celiac Disease Drugs Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Celiac Disease Drugs Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Ahead Therapeutics SL
• 17.3. Amgen Inc.
• 17.4. Amneal Pharmaceuticals LLC
• 17.5. Anokion SA
• 17.6. Barinthus Biotherapeutics plc
• 17.7. Biocon Limited
• 17.8. Bristol-Myers Squibb Company
• 17.9. Danaher Corporation
• 17.10. Dr. Falk Pharma GmbH
• 17.11. Entero Therapeutics Inc.
• 17.12. Equillium Inc.
• 17.13. F. Hoffmann-La Roche AG
• 17.14. Forte Biosciences Inc.
• 17.15. GlaxoSmithKline plc
• 17.16. Immunic Inc.
• 17.17. Johnson & Johnson Services Inc.
• 17.18. Merck & Co. Inc.
• 17.19. Mozart Therapeutics Pty Ltd
• 17.20. Parvus Therapeutics Inc.
• 17.21. Pfizer Inc.
• 17.22. Recipharm AB
• 17.23. Sanofi S.A.
• 17.24. Takeda Pharmaceutical Company Limited
• 17.25. Teva Pharmaceutical Industries Limited
• 17.26. Theravance Biopharma Inc.
• 17.27. Topas Therapeutics GmbH
• 17.28. Zedira GmbH